Abiomed Past Earnings Performance

Past criteria checks 4/6

Abiomed has been growing earnings at an average annual rate of 5.2%, while the Medical Equipment industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 12.3% per year. Abiomed's return on equity is 17.3%, and it has net margins of 24.8%.

Key information

5.2%

Earnings growth rate

4.7%

EPS growth rate

Medical Equipment Industry Growth	12.9%
Revenue growth rate	12.3%
Return on equity	17.3%
Net Margin	24.8%
Last Earnings Update	30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Abiomed makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:ABMD * Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 22	1,074	267	452	175
30 Jun 22	1,056	218	438	171
31 Mar 22	1,032	137	423	164
31 Dec 21	1,003	133	413	153
30 Sep 21	974	149	392	143
30 Jun 21	935	154	368	131
31 Mar 21	848	226	333	119
31 Dec 20	813	200	318	114
30 Sep 20	803	208	317	107
30 Jun 20	798	159	324	101
31 Mar 20	841	203	342	99
31 Dec 19	841	245	339	99
30 Sep 19	820	221	334	98
30 Jun 19	797	258	326	96
31 Mar 19	769	259	322	94
31 Dec 18	737	222	316	89
30 Sep 18	690	190	302	82
30 Jun 18	641	165	283	79
31 Mar 18	594	112	263	74
31 Dec 17	544	90	247	68
30 Sep 17	505	92	235	67
30 Jun 17	475	77	228	66
31 Mar 17	445	52	218	65
31 Dec 16	415	48	203	64
30 Sep 16	386	43	191	61
30 Jun 16	359	42	178	54
31 Mar 16	330	38	164	49
31 Dec 15	303	126	152	44

Quality Earnings: ABMD * has a large one-off gain of $61.8M impacting its last 12 months of financial results to 30th September, 2022.

Growing Profit Margin: ABMD *'s current net profit margins (24.8%) are higher than last year (15.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ABMD *'s earnings have grown by 5.2% per year over the past 5 years.

Accelerating Growth: ABMD *'s earnings growth over the past year (78.9%) exceeds its 5-year average (5.2% per year).

Earnings vs Industry: ABMD * earnings growth over the past year (78.9%) exceeded the Medical Equipment industry -3%.

Return on Equity

High ROE: ABMD *'s Return on Equity (17.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/23 08:01
End of Day Share Price	2022/12/16 00:00
Earnings	2022/09/30
Annual Earnings	2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abiomed, Inc. is covered by 26 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lawrence Neibor	Baird
Jan Wald	Benchmark Company
Michael Gorman	BTIG

Abiomed Past Earnings Performance

Past criteria checks 4/6

Key information

Recent past performance updates

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Recent updates

Abiomed, Inc. Announces Impella ECP Pivotal Study Demonstrates Safety, Efficacy for Use in High-Risk PCI

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold Mex$24m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold Mex$105m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

New 90-day high: Mex$6,952

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: Mex$6,473

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: Mex$6,240

New 90-day low: Mex$5,276

New 90-day low: Mex$5,302

Revenue beats expectations

Second quarter 2021 earnings released: EPS US$1.38

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

First quarter earnings released

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources